Martinsried/Munich, 17 December 2015. Medigene AG (Frankfurt Stock Exchange: MDG1) announced today that the Supervisory Board has resolved important changes and additions to the senior management team to better align the organisational structure with the strategic goals of the company in immuno-oncology and to expand Medigene's presence in the United States. The Supervisory Board has appointed Prof Dolores Schendel as the new Chief Executive Officer of the company, with effect from 1 February 2016. Prof Schendel joined Medigene's Executive Board as Chief Scientific Officer in May 2014. She was co-founder of Trianta Immunotherapy GmbH (now Medigene Immunotherapies GmbH), which was acquired by Medigene at the beginning of 2014 and whose platforms are the basis of Medigene's scientific strategy.
Dr Frank Mathias, who initiated as Chief Executive Officer the strategic realignment of the company with the acquisition of Trianta Immunotherapies GmbH, will hand over his office as Chief Executive Officer on the aforementioned date to Prof Dolores Schendel. Dr Mathias has decided to take on new responsibilities outside the company. In order to ensure a smooth transition, he will remain a member of the Executive Management Board of the company until the expiry of his contract on 31 March 2016. It is the Supervisory Board's wish that Dr Mathias continues to contribute his expertise to the company, for example within the scope of a mandate as a member of the Supervisory Board.
Dave Lemus, Vice Chairman of the Supervisory Board of the company, will transition with effect from 1 January 2016 to the Executive Management Board. He will assume the newly created position of the Chief Operating Officer. In addition, Mr. Lemus will be Chief Executive Officer of the US subsidiary Medigene Inc.
Contact Medigene AG
Julia Hofmann, Dr Robert Mayer
Lochhamer Str. 11
82152 Planegg/Martinsried, Germany
Tel.: +49 - 89 - 20 00 33 - 33 01